KLRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kalaris Therapeutics Inc (KLRS) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has potential based on its lead candidate TH103 and analyst optimism, the lack of financial growth, negative technical indicators, and absence of significant positive catalysts make it prudent to hold off on investing for now.
The MACD is negatively expanding, RSI is neutral at 45.493, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 9.188, with resistance at 9.963 and support at 8.413. This suggests limited upward momentum in the short term.
Analyst ratings are optimistic, with price targets of $19 and $26, citing the commercial potential of TH103 in addressing significant medical needs. Positive early efficacy data for TH103 suggests meaningful durability and potential market success.
Additionally, there is no recent news or significant insider/hedge fund activity to indicate strong near-term interest.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$11.89 million (-68.77% YoY), and a sharp decline in EPS (-97.73% YoY). Gross margin remains at 0%.
Analysts are bullish, with Chardan initiating a Buy rating and a $19 price target, and Citizens raising its price target to $26 from $20. Analysts highlight the strong early efficacy profile of TH103 and its potential to address large markets like wet AMD and diabetic retinopathy.
